Aveo advances NDA for cancer drug to FDA; Osiris' Genzyme alliance ends; Vital Therapies scores $16M from investors;

 @FierceBiotech: The French government wants Sanofi 'guarantees' on the future of Toulouse R&D. More | Follow @FierceBiotech

 @JohnCFierce: Paratek - Ph3 antibiotic, lost a big Novartis deal last year - wants a $92M IPO? Hmmmm. More | Follow @JohnCFierce

 @RyanMFierce: A crisis of credentials? Abbott came clean that choice to lead pharma unit didn't finish college. More | Follow @RyanMFierce

> Genzyme's collaboration with Osiris Therapeutics ($OSIR) on stem cell therapies Prochymal and Chondrogen has ended. Release

> Cytori Therapeutics ($CYTX) has grabbed a $4.7 million contract with the U.S. Department of Health and Human Services's Biomedical Advanced Research and Development Authority (BARDA) to advance a stem cell therapy for burns of victims of thermal or radioactive attacks. The two-year contract could be worth up to $106 million to Cytori depending on the success of the research. Article

> Aveo Oncology ($AVEO) submitted an application for approval of its experimental drug tivozanib for treatment of advanced renal cell carcinoma. Release

> San Diego-based Vital Therapies, which is developing a cellular therapy for liver failure, reported that it has raised $16 million of a planned $76 million round led by its existing investors. Item

> Novo Nordisk ($NVO) says that it won approval of its long-acting insulin drug Tresiba in Japan as the company awaits a similar nod in the U.S. Article

> An analyst at Jefferies & Co. endorses a megadeal for Roche ($RHHBY) to expand beyond cancer drugs. Item

Medical Device News

 @FierceMedDev: Boston Scientific won a CE mark for a Deep brain stimulation treatment of Parkinson's disease. More | Follow @FierceMedDev

 @MarkHFierce: Finally--the deal is done. Sony is officially investing $645M into Olympus and the two will partner on medical equipment. More | Follow @MarkHFierce

 @DamianFierce: The FDA is getting an earful from lawmakers over the hackability of medical devices. More | Follow @DamianFierce

> Medtronic makes a splash in China with $816M Kanghui buyout. Story

> A giant step forward for dissolvable medical devices. News

> Olympus, Sony ally on endoscope, med device development. Article

Pharma News

@FiercePharma: Japan OKs Novo Nordisk's long-acting insulin Tresiba, still awaiting decision from FDA. More | Follow @FiercePharma

> Roche should pick up AbbVie or BMS, analyst thinks. Story

> Regeneron keeps keeping on with Eylea. Article

> FDA tries to protect public from fake Internet pharmacies. News

And Finally… The Financial Times' pharma writer Andrew Jack reviewed a book critical about the industry he covers for the newspaper. The book's title: "Bad Pharma." Item (reg. req.)

 

 

 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.